Udit Agarwal
Cardiovascular Disease · Bismarck, NDNPI 1568753606
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $426 and has fallen 51.5% since, to $207 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in ND, where the typical reported total is $2,784.
Across 80 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$253
- Novartis$234
- E.r. Squibb & Sons, L.L.C.$232
- Amgen$174
- Pfizer$104
- Actelion Pharmaceuticals US, Inc.$96
- plus $338 from 14 others
What the payments were for
- Food & beverage$1,432100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 7 | $253 |
| Novartis | 19 | $234 |
| E.r. Squibb & Sons, L.L.C. | 17 | $232 |
| Amgen | 10 | $174 |
| Pfizer | 6 | $104 |
| Actelion Pharmaceuticals US, Inc. | 1 | $96 |
| Merck | 4 | $58 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $36 |
| Lemaitre Vascular, Inc. | 1 | $32 |
| AstraZeneca | 2 | $30 |
| Johnson & Johnson | 2 | $28 |
| United Therapeutics Corporation | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Convatec Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$108
How this compares
$1,432 in reported general payments places this provider in the 45th percentile of 35 cardiovascular disease providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 331 | $302,374 |
| EntrestoSacubitril/Valsartan | 30 | $28,742 |
| Repatha SureclickEvolocumab | 30 | $24,571 |
| XareltoRivaroxaban | 25 | $23,207 |
| JardianceEmpagliflozin | 18 | $21,828 |
| Metoprolol Succinate | 644 | $12,111 |
| Rosuvastatin Calcium | 310 | $5,412 |
| Atorvastatin Calcium | 311 | $3,663 |
| Carvedilol | 261 | $3,173 |
| Bumetanide | 98 | $2,695 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 130 | $1,814 |
| ClopidogrelClopidogrel Bisulfate | 160 | $1,723 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 28 | $1,687 |
| Losartan Potassium | 165 | $1,621 |
| Furosemide | 328 | $1,501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $104 | $302,374331 claims |
| NovartisEntresto | $234 | $28,74230 claims |
| Johnson & JohnsonXarelto | $28 | $23,20725 claims |
| Boehringer IngelheimJardiance | $16 | $21,82818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 35 cardiovascular disease providers in North Dakota.
Other cardiovascular disease in Bismarck
- Timothy PansegrauBismarck$16K
- Charles LenzBismarck$1K
- Sean RussellBismarck$1K
- Nicholas MahrBismarck$606
- Diane KraftBismarck$456
- Stanley DiedeBismarck$14
- Noah ChelliahGrand Forks$115K
- Beng Loong Isaac TeaMinot$42K
- Hussain BasrawalaGrand Forks$40K
- Thomas HaldisFargo$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.